Лабораторные маркёры полиорганной патологии при тяжёлом течении и неблагоприятных исходах инфекции SARS-CoV-2 (систематический обзор литературы)

Представлены современные научно обоснованные сведения о лабораторных параметрах пациентов с тяжёлым течением и неблагоприятными исходами инфекции SARS-CoV-2. Проанализированы полнотекстовые публикации клинических, рандомизированных и когортных исследований, систематические обзоры и мета-анализы из научных баз PubMed, Elsevier, Scopus, Google Scholar, E-library за период с 2019 по 2022 г. Определены конкретные биомаркеры, включая воспалительные и иммунологические параметры (C-реактивный белок, прокальцитонин, интерлейкин-6, D-димер, ферритин), гематологические (количество нейтрофилов, лимфоцитов, их соотношение, RDW), миокардиальные (тропонин, креатинкиназа, миоглобин), печеночные (АСТ, АЛТ, общий билирубин, альбумин) и характеризующие повреждение легких (гликопротеин Кребса фон ден Лунгена-6), которые могут быть использованы для стратификации риска, в качестве прогностических критериев неблагоприятного течения заболевания, в том числе полиорганной недостаточности, тяжёлого  течения и летального исхода пациентов с COVID-19. В исследованиях продемонстрирована роль новых биомаркеров воспалительных и системных проявлений COVID-19: прокальцитонина, кальпротектина и пресепсина.

1. Borges Do Nascimento I. J., Von Groote T. C., O’mathuna D. P., et all. Clinical, laboratory and radiological characteristics and outcomes of novel coronavirus (SARS-Cov-2) infection in humans: A systematic review and series of meta-analyses. PloS One 2020;15, E0239235. doi:10.1371/journal.pone.0239235

2. Zhang Z. L., Hou Y. L., Li D. T., Li F. Z. Laboratory findings of COVID-19: A systematic review and meta-analysis.Scand. J. Clin. Lab. Invest. 2020;80, 441–447. doi:10.1080/00365513.2020.1768587

3. Alnor A., Sandberg, M. B., Gils C., Vinholt P. J. Laboratory tests and outcome for patients with coronavirus disease 2019: A systematic review and meta-analysis.J. Appl. Lab. Med. 2020;5, 1038–1049. doi:10.1093/jalm/jfaa098

4. Elshazli R. M., Toraih E. A., Elgaml A., et al. Diagnostic and prognostic value of hematological and immunological markers in COVID-19 infection: A meta-analysis of 6320 patients.PloS One. 2020;15, E0238160. doi:10.1371/journal.pone.0238160

5. Kermali M., Khalsa R. K., Pillai K., et all. The role of biomarkers in diagnosis of COVID-19 – a systematic review. Life Sci. 2020;254, 117788. doi:10.1016/j.lfs.2020.117788

6. Rostami M., Khoshnegah Z., Mansouritorghabeh H. Hemostatic system (Fibrinogen level, d-dimer, and FDP) in severe and non-severe patients with COVID-19: A systematic review and meta-analysis.Clin. Appl. Thromb. Hemost.2021;27, 10760296211010973. doi:10.1177/10760296211010973

7. Liu Y., Cai J., Wang C., Jin J., Qu L. A systematic review and meta-analysis of incidence, prognosis, and laboratory indicators of venous thromboembolism in hospitalized patients with coronavirus disease 2019. J. Vasc. Surg. Venous Lymphat Disord. 2021;9, 1099–1111.E6. doi: 10.1016/j.jvsv.2021.01.012

8. Jafrin S., Aziz M. A., Islam M. S. Elevated levels of pleiotropic interleukin-6 (IL-6) and interleukin-10 (IL-10) are critically involved with the severity and mortality of COVID-19: An updated longitudinal meta-analysis and systematic review on 147 studies.biomark. Insights.2022;17, 11772719221106600. doi: 10.37766/inplasy2022.4.0046

9. Zinellu, A., Mangoni, A. A. Serum complement C3 and C4 and COVID-19 severity and mortality: A systematic review and meta-analysis with meta-regression. Front. Immunol.2021;12,696085. doi:10.3389/fimmu.2021.696085

10. Iwamura A. P. D., Tavares Da Silva, M. R., Hummelgen A. L., et al. Immunity and inflammatory biomarkers in COVID-19: A systematic review.Rev. Med. Virol. 2021;31, E2199. doi:10.1002/rmv.2199

11. Udeh R., Advani S., De Guadiana Romualdo, L. G., Dolja-Gore X. Calprotectin, an emerging biomarker of interest in COVID-19: A systematic review and meta-analysis.J. Clin. Med. 2021;10. doi:10.3390/jcm10040775

12. Carpene G., Negrini, D., Henry B. M., et all. Homocysteine in coronavirus disease (COVID-19): A systematic literature review. Diagnosis (Berl).2022;9, 306–310. doi:10.1515/dx-2022-0042

13. Zou Q., Wen W., Zhang, X. C. Presepsin as a novel sepsis biomarker. World J. Emerg. Med. 2014;5, 16–19. doi: 10.5847/wjem.j.issn.1920-8642.2014.01.002

14. Ahmed S., Mansoor M., Shaikh, M. S., Siddiqui, I. Presepsin as a predictive biomarker of severity in COVID-19: A systematic review.Indian J. Crit. Care Med. 2021;25, 1051–1054. doi:10.5005/jp-journals-10071-23967

15. Tian W., Jiang W., Yao J., et al. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis.J. Med. Virol. 2020;92, 1875–1883. doi:10.1002/jmv.26050;

16. Ulloque-Badaracco J. R., Hernandez-Bustamante E. A., Herrera-Anazco P., Benites-Zapata V. A. Prognostic value of apolipoproteins in COVID-19 patients: A systematic review and meta-analysis. Travel Med. Infect. Dis. 2021;44, 102200. doi:10.1016/j.tmaid.2021.102200

17. Figliozzi S., Masci P. G., Ahmadi N., et al. (). Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis.Eur. J. Clin. Invest. 2020;50, E13362. doi:10.1111/eci.13362

18. Malik P., Patel U., Mehta D., et al. Biomarkers and outcomes of COVID-19 hospitalisations: Systematic review and meta-analysis.BMJ Evid Based Med. 2021;26, 107–108. doi:10.1136/bmjebm-2020-111536

19. Shi C., Wang L., Ye J., et al. Predictors of mortality in patients with coronavirus disease 2019: A systematic review and metaanalysis. BMC Infect. Dis. 2021;21, 663. doi:10.1186/s12879-021-06369-0

20. Xiang G., Xie L., Chen Z., et al. Clinical risk factors for mortality of hospitalized patients with COVID-19: Systematic review and meta-analysis.Ann. Palliat Med. 2021;10, 2723– 2735. doi:10.21037/apm-20-1278

21. Wacker C., Prkno A., Brunkhorst F. M., Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: A systematic review and metaanalysis.Lancet Infect. Dis. 2013;13, 426–435. doi:10.1016/S1473-3099(12)70323-7

22. Huang I., Pranata, R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): Systematic review and meta-analysis.J. Intensive Care. 2020;8, 36. doi:10.1186/s40560-020-00453-4

23. Hariyanto T. I., Japar K. V., Kwenandar F., et al. Inflammatory and hematologic markers as predictors of severe outcomes in COVID-19 infection: A systematic review and meta-analysis. Am. J. Emerg. Med. 2021;41, 110–119. doi:10.1016/j.ajem.2020.12.076

24. Zheng Z., Peng F., Xu B., et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and metaanalysis.J. Infect. 2020;81, E16–E25. doi:10.1016/j.jinf.2020.04.021

25. Ahmed S., Jafri L., Hoodbhoy Z., Siddiqui I. Prognostic value of serum procalcitonin in COVID-19 patients: A systematic review. Indian J. Crit. Care Med. 2021;25, 77–84. doi:10.5005/jp-journals-10071-23706

26. Melo A. K. G., Milby K. M., Caparroz A., et al.Biomarkers of cytokine storm as redflags for severe and fatal COVID-19 cases: A living systematic review and meta-analysis. PloS One 2021;16, E0253894. doi:10.1371/journal.pone.025389

27. Zare M. E., Wang Y., Nasir Kansestani A., et all. Procalcitonin has good accuracy for prognosis of critical condition and mortality in COVID-19: A diagnostic test accuracy systematic review and meta-analysis. Iran J. Allergy Asthma Immunol. 2020;19, 557–569. doi:10.18502/ijaai.v19i6.4926

28. Huang I., Pranata R., Lim M. A., et all. Creactive protein, procalcitonin, d-dimer, and ferritin in severe coronavirus disease-2019: A meta-analysis.Ther. Adv. Respir. Dis. 2020;14, 1753466620937175. doi:10.1177/1753466620937175

29. Terpos E., Ntanasis-Stathopoulos I., Elalamy I., et al. Hematological findings and complications of COVID-19. Am. J. Hematol. 2020;95, 834–847. doi:10.1002/ajh.25829;

30. Pranata, R., Lim M. A., Yonas E., et all. Thrombocytopenia as a prognostic marker in COVID-19 patients: Diagnostic test accuracy meta-analysis. Epidemiol. Infect. 2021;149, E40. doi:10.1017/S0950268821000236

31. Lim A. Y. H., Goh J. L., Chua M. C. W., et all. Temporal changes of haematological and radiologicalfindings of the COVID-19 infection-a review of literature. BMC Pulm Med. 2021;21, 37. doi:10.1186/s12890-020-01389-z

32. Chua P. E. Y., Shah S. U., Gui H., et all. Epidemiological and clinical characteristics of non-severe and severe pediatric and adult COVID-19 patients across different geographical regions in the early phase of pandemic: A systematic review and meta-analysis of observational studies. J. Investig. Med. 2021;69, 1287–1296. doi:10.1136/jim-2021-001858

33. Kovalic A. J., Huang G., Thuluvath P. J., Satapathy S. K. Elevated liver biochemistries in hospitalized Chinese patients with severe COVID-19: Systematic review and meta-analysis. Hepatology2021;73, 1521–1530. doi:10.1002/hep.31472

34. Alkhatip A., Kamel M. G., Hamza M. K., et al. The diagnostic and prognostic role of neutrophil-To-Lymphocyte ratio in COVID-19: A systematic review and meta-analysis. Expert Rev. Mol. Diagn. 2021;21, 505–514. doi:10.1080/14737159.2021.1915773

35. Li X., Liu C., Mao Z., et al. Predictive values of neutrophil-To-Lymphocyte ratio on disease severity and mortality in COVID-19 patients: A systematic review and meta-analysis. Crit. Care.2020;24, 647. doi:10.1186/s13054-020-03374-8

36. Simadibrata D. M., Calvin J., Wijaya A. D., Ibrahim, N. A. A. Neutrophil-To-Lymphocyte ratio on admission to predict the severity and mortality of COVID-19 patients: A meta-analysis. Am. J. Emerg. Med. 2021;42, 60–69.doi:10.1016/j.ajem.2021.01.006

37. Sarkar P. G., Pant P., Kumar J., Kumar A. Does neutrophil-ToLymphocyte ratio At admission predict severity and mortality in COVID-19 patients? a systematic review and meta-analysis. Indian J. Crit. Care Med. 2022;26,361–375. doi:10.5005/jp-journals-10071-24135

38. Sarkar S., Khanna P., Singh A. K. The impact of neutrophil lymphocyte count ratio in COVID-19: A systematic review and meta-analysis. J. Intensive Care Med. 2022;37, 857–869. doi:10.1177/08850666211045626

39. Parthasarathi A., Padukudru S., Arunachal S., et al. The role of neutrophil-To-Lymphocyte ratio in risk stratification and prognostication of COVID-19: A systematic review and metaanalysis.Vaccines (Basel) 2022;10. doi:10.3390/vaccines10081233

40. Taneri P. E., Gomez-Ochoa S. A., Llanaj E., et al. Anemia and iron metabolism in COVID-19: A systematic review and meta-analysis. Eur. J. Epidemiol. 2020;35, 763–773. doi:10.1007/s10654-020-00678-5

41. Kaushal K., Kaur H., Sarma P., et al. Serum ferritin as a predictive biomarker in COVID-19. a systematic review, meta-analysis and meta-regression analysis. J. Crit. Care2022;67, 172–181. doi: 10.1016/j.jcrc.2021.09.023

42. Zinellu A., Mangoni A. A. Red blood cell distribution width, disease severity, and mortality in hospitalized patients with SARS-Cov-2 infection: A systematic review and meta-analysis. J. Clin. Med. 2021;10(2),286. doi:10.3390/jcm10020286

43. Lee J. J., Montazerin S. M., Jamil A., et al. Association between red blood cell distribution width and mortality and severity among patients with COVID-19: A systematic review and meta-analysis. J. Med. Virol. 2021;93, 2513–2522. doi:10.1002/jmv.26797

44. Rostami M., Mansouritorghabeh H. D-dimer level in COVID-19 infection: A systematic review. Expert Rev. Hematol. 2020;13,1265–1275.doi:10.1080/17474086.2020.1831383

45. Zhang X., Yang X., Jiao H., Liu X. Coagulopathy in patients with COVID-19: A systematic review and meta-analysis. Aging (Albany NY). 2020;12, 24535– 24551. doi:10.18632/aging.104138

46. Xiang G., Hao S., Fu C., et al. The effect of coagulation factors in 2019 novel coronavirus patients: A systematic review and meta-analysis. Med. (Baltimore) 2021;100, E24537. doi:10.1097/MD.0000000000024537

47. Liu Y., Cai J., Wang C., Jin J., Qu, L. (b). A systematic review and meta-analysis of incidence, prognosis, and laboratory indicators of venous thromboembolism in hospitalized patients with coronavirus disease 2019. J. Vasc. Surg. Venous Lymphat Disord.2021;9, 1099–1111.E6. doi: 10.1016/j.jvsv.2021.01.012

48. Woller S. C., De Wit K., Robert-Ebadi H., et al. A systematic review of biomarkers among hospitalized patients with COVID-19 predictive of venous thromboembolism: A communication from the predictive and diagnostic variables scientific and standardization committee of the ISTH. Res. Pract. Thromb. Haemost. 2022;6, E12786. doi:10.1002/rth2.12786

49. Duz M. E., Balci A., Menekse E. (). D-dimer levels and COVID-19 severity: Systematic review and meta-analysis. Tuberk Toraks 2020;68, 353–360. doi:10.5578/tt.70351; Simadibrata D. M., Lubis A. M. D-dimer levels on admission and all-cause mortality risk in COVID-19 patients: A meta-analysis. Epidemiol. Infect. 2020;148, E202. doi:10.1017/S0950268820002022

50. Sakka M., Connors J.M., Hekimian G., et al. Association between d-dimer levels and mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and pooled analysis. J. Med. Vasc.2020;45, 268–274. doi:10.1016/j.jdmv.2020.05.003

51. Lima W. G., Barra A., Brito J. C. M., Nizer W. S. C. (). D-dimer serum levels as a biomarker associated for the lethality in patients with coronavirus disease 2019: A meta-analysis. Blood Coagul Fibrinolysis 2020;31, 335–338. doi: 10.1097/MBC.0000000000000927

52. Paliogiannis P., Mangoni A. A., Dettori P., et all. D-dimer concentrations and COVID-19 severity: A systematic review and meta-analysis. Front. Public Health 2020;8, 432. doi: 10.3389/fpubh.2020.00432

53. Ji H. J., Su Z., Zhao R., et al. Insufficient hyperfibrinolysis in COVID-19: A systematic review of thrombolysisbased on meta-analysis and meta-regression. Medrxiv. 2020;1–25. doi: 10.1101/2020.09.07.20190165; Varikasuvu S. R., Varshney S., Dutt N., et al. D-dimer, disease severity, and deaths (3D-study) in patients with COVID-19: A systematic review and meta-analysis of 100 studies. Sci. Rep. 2021;11, 21888. doi:10.1038/s41598-021-01462-5

54. Nugroho J., Wardhana A., Maghfirah I., et al. Relation-ship of d-dimer with severity and mortality in SARSCov-2 patients : A meta-analysis. Int. J. Lab. Hematol. 2021;43, 110–115. doi:10.1111/ijlh.13336; Chua P. E. Y., Shah S. U., Gui H., et all. Epidemiological and clinical characteristics of non-severe and severe pediatric and adult COVID-19 patients across different geographical regions in the early phase of pandemic: A systematic review and meta-analysis of observational studies. J. Investig. Med. 2021;69, 1287–1296. doi:10.1136/jim-2021-001858

55. Varikasuvu S. R., Varshney S., Dutt N., et al. D-dimer, disease severity, and deaths (3D-study) in patients with COVID-19: A systematic review and meta-analysis of 100 studies. Sci. Rep. 2021;11, 21888. doi:10.1038/s41598-021-01462-5

56. Zhao R., Su Z., Komissarov A. A., et al. Associations of d-dimer on admission and clinical features of COVID-19 patients: A systematic review, meta-analysis, and meta-regression. Front. Immunol. 2021;12, 691249. doi:10.3389/fimmu.2021.691249

57. Hariyanto T. I., Japar K. V., Kwenandar F., et al. Inflammatory and hematologic markers as predictors of severe out-comes in COVID-19 infection: A systematic review and meta-analysis. Am. J. Emerg. Med. 2021;41, 110–119. doi:10.1016/j.ajem.2020.12.076

58. Lampsas S.,Tsaplaris P.,Pantelidis P., et al. The role of endothelial related circulating biomarkers in COVID-19. a systematic review and meta-analysis. Curr. Med. Chem. 2021.29(21), 3790–3805. doi:10.2174/0929867328666211026124033

59. Andrianto Al-Farabi M. J., Nugraha R. A., et all.. Biomarkers of endothelial dysfunction and outcomes in coronavirus disease 2019 (COVID-19) patients: A systematic review and meta-analysis. Microvasc Res. 2021.138, 104224. doi:10.1016/j.mvr.2021.104224

60. Momtazmanesh S., Shobeiri P., Hanaei S., et all. Cardiovascular disease in COVID-19: A systematic review and meta-analysis of 10,898 patients and proposal of a triage risk stratification tool. Egypt Heart J. 2020;72, 41. doi:10.1186/s43044-020-00075-z

61. Vakhshoori M., Emami S. A., Heidarpour M., et all. Corona virus disease 2019 (COVID-19) and its effect on renal system, a systematic review and meta-analysis. Iran J. Kidney Dis. 2020;14, 419–438

62. Long J., Luo Y., Wei Y. The effect of cardiovascular disease and acute cardiac injury on fatal COVID-19: A meta-analysis. Am. J. Emerg. Med. 2021;48, 128–139. doi:10.1016/j.ajem.2021.04.013

63. Shoar S., Hosseini F., Naderan M., Mehta J. L. Meta-analysis of cardiovascular events and related biomarkers comparing survivors versus nonsurvivors in patients with COVID-19. Am. J. Cardiol. 2020;135, 50–61. doi:10.1016/j.amjcard.2020.08.044

64. Pellicori P., Doolub G., Wong C. M., et al. COVID-19 and its cardiovascular effects: A systematic review of prevalence studies. Cochrane Database Syst. Rev. 2021;3, CD013879. doi: 10.1002/14651858.CD013879

65. Jaiswal V., Sarfraz Z., Sarfraz A., et al.(). COVID-19 infection and myocarditis: A state-Of-The-Art systematic review. J. Prim Care Community Health.2021;12, 21501327211056800. doi:10.1177/21501327211056800

66. Shafi A. M. A., Shaikh S. A., Shirke M. M., et all. Cardiac manifestations in COVID-19 patients-a systematic review. J. Card Surg. 2020;35,1988–2008. doi:10.1111/jocs.14808;

67. Alzahrani S. H., Al-Rabia M. W. Cardiac injury biomarkers and the risk of death in patients with COVID-19: A systematic review and meta-analysis. Cardiol. Res. Pract.2021, 9363569. doi:10.1155/2021/9363569

68. Parohan M., Yaghoubi S., Seraji A. Cardiac injury is associated with severe outcome and death in patients with coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of observational studies. Eur. Heart J. Acute Cardiovasc. Care.2020;9, 665–677. doi:10.1177/2048872620937165

69. Li J. W., Han T. W., Woodward M., et al. The impact of 2019 novel coronavirus on heart injury: A systematic review and meta-analysis. Prog. Cardiovasc. Dis. 2020;63, 518–524. doi: 10.1016/j.pcad.2020.04.008; Walker C., Deb S., Ling H., Wang Z. Assessing the elevation of cardiac biomarkers and the severity of COVID-19 infection: A meta-analysis. J. Pharm. Pharm. Sci. 2020;23, 396–405. doi:10.18433/jpps31501;

70. An W., Kang J. S., Wang Q., Kim, T. E. Cardiac biomarkers and COVID-19: A systematic review and meta-analysis. J. Infect. Public Health 2021;14,1191–1197. doi:10.1016/j.jiph.2021.07.016

71. Zinellu A., Sotgia S., Fois A. G., Mangoni A. A. Serum CK-MB, COVID-19 severity and mortality: An updated systematic review and meta-analysis with meta-regression. Adv. Med. Sci. 2021;66, 304–314. doi: 10.1016/j.advms.2021.07.001

72. Qiang Z., Wang B., Garrett B. C., et all. Coronavirus disease 2019: A comprehensive review and meta-analysis on cardiovascular biomarkers. Curr. Opin. Cardiol. 2021;36, 367– 373. doi: 10.1097/HCO.0000000000000851

73. Paliogiannis P., Mangoni A. A., Dettori P., et all. D-dimer concentrations and COVID-19 severity: A systematic review and meta-analysis. Front. Public Health.2020;8, 432. doi: 10.3389/fpubh.2020.00432

74. Zheng Z., Peng F., Xu B., et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J. Infect. 2020;81, E16–E25. doi:10.1016/j.jinf.2020.04.021

75. Martinez-Outschoorn U. E., Prisco M., Ertel A., et al. Ketones and lactate increase cancer cell “Stemness,” driving recurrence, metastasis and poor clinical outcome in breast cancer: Achieving personalized medicine Viametabolo-genomics. Cell Cycle.2011;10, 1271–1286. doi:10.4161/cc.10.8.15330

76. Erez A., Shental O., Tchebiner J. Z., et al. Diagnostic and prognostic value of very high serum lactate dehydrogenase in admitted medical patients. Isr. Med. Assoc. J. 2014;16, 439–443

77. Assiri A., Al-Tawfiq J. A., Al-Rabeeah A. A., et al. Epidemiological, demographic, and clinical characteristics of 47 cases of middle East respiratory syndrome coronavirus disease from Saudi Arabia: A descriptive study. Lancet Infect. Dis. 2013;13, 752–761. doi:10.1016/S1473-3099(13)70204-4.

78. Alnor A., Sandberg M. B., Gils C., Vinholt P. J. Laboratory tests and outcome for patients with coronavirus disease 2019: A systematic review and meta-analysis. J. Appl. Lab. Med. 2020;5, 1038–1049. doi:10.1093/jalm/jfaa098

79. Kermali M., Khalsa R. K., Pillai K., et all. The role of biomarkers in diagnosis of COVID-19 – a systematic review. Life Sci. 2020;254, 117788.doi:10.1016/j.lfs.2020.117788

80. Zhang Z. L., Hou Y. L., Li D. T., Li F. Z. Laboratory findings of COVID-19: A systematic review and meta-analysis. Scand. J. Clin. Lab. Invest. 2020;80,441–447. doi:10.1080/00365513.2020.1768587

81. Wibowo A., Pranata R., Akbar M. R., et all. Prognostic performance of troponin in COVID-19: A diagnostic metaanalysis and meta-regression. Int. J. Infect. Dis. 2021;105, 312–318. doi: 10.1016/j.ijid.2021.02.113

82. Toraih E.A.,Elshazli R.M.,Hussein M.H., et al. Association of cardiac biomarkers and comorbidities with increased mortality, severity, and cardiac injury in COVID-19 patients: A meta-regression and decision tree analysis.J. Med. Virol. 2020;92, 2473–2488. doi:10.1002/jmv.26166

83. Vakhshoori M., Heidarpour M., Shafie D., et all. Acute cardiac injury in COVID-19: A systematic review and meta-analysis. Arch. Iran Med. 2020;23, 801–812. doi:10.34172/aim.2020.107

84. Chaudhary R., Garg J., Houghton D.E., et al. Thromboinflammatory biomarkers in COVID-19: Systematic review and meta-analysis of 17,052 patients. Mayo Clin. Proc. Innov.Qual Outcomes. 2021;5, 388–402. doi:10.1016/j.mayocpiqo.2021.01.009

85. Rathore S. S., Rojas G. A., Sondhi M., et al. Myocarditis associated with covid-19 disease: A systematic review of published case reports and case series. Int. J. Clin. Pract. 2021;75, E14470. doi:10.1111/ijcp.14470

86. Ramadan M. S., Bertolino L., Zampino R., et all. Hospital Cardiovascular Infection Study, G. Cardiac sequelae after coronavirus disease 2019 recovery: A systematic review. Clin. Microbiol. Infect. 2021;27, 1250–1261. doi:10.1016/j.cmi.2021.06.015

87. Zinellu, A., Mangoni, A. A. Serum complement C3 and C4 and COVID-19 severity and mortality: A systematic review and meta-analysis with meta-regression. Front. Immunol. 2021;12, 696085. doi:10.3389/fimmu.2021.696085

88. Pranata R., Huang I., Lukito, A. A., Raharjo S. B. Elevated nterminal pro-brain natriuretic peptide is associated with increased mortality in patients with COVID-19: Systematic review and meta-analysis. Postgrad Med. J. 2020.96,387–391. doi:10.1136/postgradmedj-2020-137884

89. Ma C., Tu D., Gu J., et al. The predictive value of myoglobin for COVID-19-Related adverse outcomes: A systematic review and meta-analysis. Front. Cardiovasc. Med. 2021;8, 757799. doi:10.3389/fcvm.2021.757799

90. Ulloque-Badaracco J. R., Hernandez-Bustamante E. A., Herrera-Anazco P., Benites-Zapata V. A. Prognostic value of apolipoproteins in COVID-19 patients: A systematic review and meta-analysis. Travel Med. Infect. Dis. 2021;44, 102200. doi:10.1016/j.tmaid.2021.102200

91. Zinellu, A., Paliogiannis, P., Carru, C., Mangoni, A. A. Serum hydroxybutyrate dehydrogenase and COVID-19 severity and mortality: A systematic review and meta-analysis with meta-regression. Clin.Exp.Med. 2021.doi:10.1007/s10238-021-00777-x

92. An W., Kang J. S., Wang Q., Kim T. E. Cardiac biomarkers and COVID-19: A systematic review and meta-analysis. J. Infect. Public Health. 2021;14, 1191–1197. doi:10.1016/j.jiph.2021.07.016

93. Dy L. F., Lintao R. C. V., Cordero C. P., et all. Prevalence and prognostic associations of cardiac abnormalities among hospitalized patients with COVID-19: A systematic review and meta-analysis. Sci.Rep. 2021;11, 8449. doi:10.1038/s41598-021-87961-x

94. Vakhshoori M., Emami S. A., Heidarpour M., et all. Corona virus disease 2019 (COVID-19) and its effect on renal system, a systematic review and meta-analysis. Iran J. Kidney Dis. 2020;14, 419–438

95. Lim M. A., Pranata R., Huang I., et all. Multiorgan failure with emphasis on acute kidney injury and severity of COVID-19: Systematic review and meta-analysis. Can. J. Kidney Health Dis. 2020;7, 2054358120938573. doi:10.1177/2054358120938573

96. Tian W., Jiang W., Yao J., et al. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis. J. Med. Virol. 2020;92, 1875–1883. doi:10.1002/jmv.26050

97. Ahmed J., Rizwan T., Malik F., et al. Covid-19 and liver injury: A systematic review and meta-analysis. Cureus2020;12,E9424. doi:10.7759/cureus.9424

98. Abdulla S., Hussain A., Azim D., et al. Covid-19-Induced hepatic injury: A systematic review and metaanalysis. Cureus.2020;12, E10923. doi:10.7759/cureus.10923

99. Shokri Afra H., Amiri-Dashatan N., Ghorbani F., et all. Positive association between severity of COVID-19 infection and liver damage: A systematic review and meta-analysis.Gastroenterol. Hepatol. Bed Bench.2020;13, 292–304

100. Aziz M., Haghbin H., Lee-Smith W. Gastrointestinal predictors of severe COVID-19: Systematic review and meta-analysis. Ann. Gastroentero.2020;l.33, 615–630. doi:10.20524/aog.2020.0527

101. Zarifian A., Zamiri Bidary M., Arekhi S., et al. Gastrointestinal and hepatic abnormalities in patients with confirmed COVID-19: A systematic review and meta-analysis. J. Med. Virol. 2021;93, 336–350. doi:10.1002/jmv.26314

102. Ye L., Chen B., Wang Y., et al. Prognostic value of liver biochemical parameters for COVID-19 mortality. Ann. Hepatol. 2021;21, 100279. doi:10.1016/j.aohep.2020.10.007

103. Aziz M., Fatima R., Lee-Smith W., Assaly R. The association of low serum albumin level with severe COVID-19: A systematic review and metaanalysis. Crit. Care.2020;24, 255. doi:10.1186/s13054-020-02995-3

104. Hariyanto T. I., Japar K. V., Kwenandar F., et al. Inflammatory and hematologic markers as predictors of severe outcomes in COVID-19 infection: A systematic review and meta-analysis. Am. J. Emerg. Med. 2021;41, 110–119. doi:10.1016/j.ajem.2020.12.076

105. Wan S., Li M., Ye Z., et all. CT manifestations and clinical characteristics of 1115 patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Acad. Radiol. 2020.27, 910–921. doi:10.1016/j.acra.2020.04.033

106. Pramana Witarto A., Samarta Witarto B., Er Putra A. J., et all. Serum Krebs Von den lungen-6 for predicting the severity of COVID-19 lung injury: A systematic review and meta-analysis. Iran BioMed. J.2021.25, 381–389. doi:10.52547/ibj.25.6.381

107. Naderi, N., Rahimzadeh, M. Krebs Von Den lungen-6 (KL-6) as a clinical marker for severe COVID-19: A systematic review and meta-analyses. Virology.2022.566, 106–113. doi:10.1016/j.virol.2021.11.006